Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Reassuring Data on Cancer Risk with Contemporary RA Drugs

Reuters Staff  |  September 20, 2017

NEW YORK (Reuters Health)—A large Swedish study1 provides reassuring data on the risk of cancer in patients with rheumatoid arthritis (RA) treated with tumor necrosis factor (TNF) inhibitors or with tocilizumab, abatacept or rituximab.

Overall, the risk of malignant neoplasms did not differ between patients treated with a first anti-TNF drug; a second anti-TNF drug; tocilizumab, abatacept, rituximab; or conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), with the possible exception of an increased risk of squamous cell skin cancer in patients treated with abatacept, the study team reported online September 18 in JAMA Internal Medicine.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Considering the widespread and increasing use of biological disease-modifying anti-rheumatic drugs (bDMARDs) to treat chronic inflammatory conditions, and the concern that immunomodulation may alter cancer risk and progression, the limited available data on use of these therapies as used in clinical practice and cancer risks are a concern,” Dr. Hjalmar Wadstrom from the Karolinska Institutet in Stockholm and the Anti-Rheumatic Therapy in Sweden (ARTIS) study group, note in their paper.

Using registry data, they identified cohorts of RA patients starting treatment with tocilizumab, abatacept, or rituximab; those using a TNF inhibitor as a first-ever or second-ever bDMARD; a biologics-naive cohort treated with csDMARDs; and a general population comparator cohort.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The dataset totaled 15,129 initiations of a TNF inhibitor as the first or second bDMARD, 7,405 initiations of other bDMARDs, and 46,610 csDMARD users, as well as 107,491 adults in the general population.

Across the cohorts, the mean age varied from 58 to 64, and the proportion of women varied from 71% to 80%.

“In this study, to our knowledge one of the largest observational studies on the risk of malignant neoplasms in RA patients treated with bDMARDs to date, we found that the overall risk of developing cancer among patients with RA initiating treatment with TNF inhibitors or non-TNF inhibitors, as used in clinical practice, did not differ from that of patients with bDMARD-naive RA,” Dr. Wadstrom and colleagues report.

“We found no increased risk of malignant neoplasms overall, with 95% CIs (confidence intervals) excluding clinically meaningfully increased risks. In addition, we found no increase in risk among patients starting TNF inhibitor as second bDMARD,” they say.

There were no “signals” of increased risks for any specific cancer types, with the exception of abatacept, with the data suggesting an increased risk of squamous cell skin cancer (adjusted hazard ratio, 2.15), although the researchers caution that this observation needs to be replicated.

A limitation of the study is that follow-up time and statistical power are “inherently limited to less than 10 years,” given the relatively recent introduction of non-TNF inhibitor therapy in RA.

Despite this, they say it can be concluded from this study that “short-to medium-term use of tocilizumab, abatacept, rituximab, or anti-TNF drugs seems to be safe with regard to risks of incident cancer.”

Reference

  1. Wadström H, Frisell T, Askling J, et al. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden. JAMA Intern Med. 2017 Sept 18. [Epub ahead of print]

 

 

 

Page: 1 2 | Multi-Page
Share: 

Filed under:Drug UpdatesRheumatoid Arthritis Tagged with:Cancercancer riskKarolinska Institutet in StockholmRheumatoid Arthritis (RA)Swedish studytumor necrosis factor (TNF) inhibitors

Related Articles

    Malignant Atrophic Papulosis Is Challenging to Diagnose, Treat

    July 1, 2014

    Patient histories, clinician reports of condition also called Köhlmeier-Degos disease underscore need for integrated, multidisciplinary care

    Are We Playing It Safe?

    October 1, 2010

    Tumor necrosis factor alpha inhibition and the risk of solid malignancies

    TNF Blockade for SLE

    September 1, 2010

    Reckless approach versus missed opportunity?

    Lightspring/shutterstock.com

    The Immune Checkpoint Inhibitors Unleashed to Fight Cancer

    May 17, 2017

    A 53-year-old female presented to the clinic for severe polyarticular joint pain and was found to have a seronegative inflammatory arthritis. Six months before, she had completed 10 months of treatment for stage IV metastatic melanoma with the immune checkpoint inhibitors, nivolumab and ipilimumab, achieving complete remission of her cancer. She said that throughout her…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences